Faster than Viagra: New Gel creates erection in Minutes

gel

Shares in a British pharmaceutical company have surged after successful trials for its fast acting gel to combat erectile dysfunction.

Trials with 232 men found the gel had the desired effect with the vast majority – 82 per cent – within ten minutes.

That makes the gel a serious rival to Viagra, which generally takes 30 minutes to work.
As such, the British manufacturer, Futuru Medical, could be line to grab a share of a global market for erectile dysfunction treatments worth $5billion a year.

Shares in the Guildford based company more than doubled on Wednesday after it revealed details of the successful trial of the gel, which is known as MED2002 and branded as Eroxon.

The firm said: ‘The speed of onset of action of MED2002 was rapid, partly reflecting the method of application with the gel being applied directly to the penis.

‘82per cent of patients with mild erectile dysfunction(ED) had an onset of action within 10 minutes and in 54per cent of mild ED patients onset was within 5 minutes.
‘This rapid onset of action means that MED2002 has the potential of being the world’s fastest-acting treatment for ED.’

It said: ‘No major safety concerns were identified. No serious adverse events or serious adverse reactions were recorded and there were no drop-outs from the study owing to side-effect issues.’

As a result, it said the gel could be sold as an over the counter product as well as being offered through prescription.

Chief executive James Barder said: ‘We certainly think it’s a breakthrough product.
‘The key issues with the other products are speed of onset, all the other products require pre-planning and offer no spontaneity.

‘Eroxon, however, can form part of sexual foreplay, which is very important for men. We also have a very safe product, with no serious adverse events or effects occurring during the study.

‘We believe this could become a first-line therapy for physicians, as topical treatments will often be the preferred first choice product for doctors.’

He added: ‘This is a game-changer for us.

‘If and when we get global approval, a 20pc market share is not unreasonable, which could lead to $1bn in annual sales.’

The active ingredient in the gel is Glyceryl Trinitrate (GTN) a drug that has been used to treat angina sufferers in the past and has the effect of dilating blood vessels.

The GTN dilates the arteries in the penis, allowing them to fill with blood. The firm said: ‘Following sexual stimulation, a natural erection occurs.’

The company is in talks with regulators in the UK and the US to bring the product to the market. British men could be the first to buy it over the counter.

It is thought the company will sell the product to a third party big brand consumer care firm, which will pay a royalty for each tube sold.

The company already has one product on the market – a condom that uses the Eroxon gel in a different formulation to help maintain an erection.

It is being sold in Holland under the Blue Diamond brand and is due to launch in the UK and the rest of northern Europe in the next 12 to 18 months.

Futura Medical, which floated on the Aim market in 2001, also has other products in the pipeline, including pain relief gels using ibuprofen and diclofenac.

Source: dailymail.co.uk

Share our story:

2 comments

  • Paul Lawrence

    I recently underwent nerve sparing prostatectomy and now suffer from ED. I would like to be considered for trials or try your new cream. I am 68 and in a steady loving relationship, I am otherwise fit and healthy as far as I know. Can you help, please.
    Regards Paul

  • Bud Galloway

    I would like to be considered as a trial participate for the Eroxon Gel study group. I
    am 83 years old and in good health.

Leave a Reply

Your email address will not be published. Required fields are marked *